Cargando…

Routes of non-traditional entry into buprenorphine treatment programs

BACKGROUND: Excessive prescribing, increased potency of opioids, and increased availability of illicit heroin and synthetic analogs such as fentanyl has resulted in an increase of overdose fatalities. Medications for opioid use disorder (MOUD) significantly reduces the risk of overdose when compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Champagne-Langabeer, Tiffany, Swank, Michael W., Langabeer, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972002/
https://www.ncbi.nlm.nih.gov/pubmed/31959194
http://dx.doi.org/10.1186/s13011-020-0252-z
_version_ 1783489832230584320
author Champagne-Langabeer, Tiffany
Swank, Michael W.
Langabeer, James R.
author_facet Champagne-Langabeer, Tiffany
Swank, Michael W.
Langabeer, James R.
author_sort Champagne-Langabeer, Tiffany
collection PubMed
description BACKGROUND: Excessive prescribing, increased potency of opioids, and increased availability of illicit heroin and synthetic analogs such as fentanyl has resulted in an increase of overdose fatalities. Medications for opioid use disorder (MOUD) significantly reduces the risk of overdose when compared with no treatment. Although the use of buprenorphine as an agonist treatment for opioid use disorder (OUD) is growing significantly, barriers remain which can prevent or delay treatment. In this study we examine non-traditional routes which could facilitate entry into buprenorphine treatment programs. METHODS: Relevant, original research publications addressing entry into buprenorphine treatment published during the years 1989–2019 were identified through PubMed, PsychInfo, PsychArticles, and Medline databases. We operationalized key terms based on three non-traditional paths: persons that entered treatment via the criminal justice system, following emergencies, and through community outreach. RESULTS: Of 462 screened articles, twenty studies met the inclusion criteria for full review. Most studies were from the last several years, and most (65%) were from the Northeastern region of the United States. Twelve (60%) were studies suggesting that the criminal justice system could be a potentially viable entry route, both pre-release or post-incarceration. The emergency department was also found to be a cost-effective and viable route for screening and identifying individuals with OUD and linking them to buprenorphine treatment. Fewer studies have documented community outreach initiatives involving buprenorphine. Most studies were small sample size (mean = < 200) and 40% were randomized trials. CONCLUSIONS: Despite research suggesting that increasing the number of Drug Addiction Treatment Act (DATA) waived physicians who prescribe buprenorphine would help with the opioid treatment gap, little research has been conducted on routes to increase utilization of treatment. In this study, we found evidence that engaging individuals through criminal justice, emergency departments, and community outreach can serve as non-traditional treatment entry points for certain populations. Alternative routes could engage a greater number of people to initiate MOUD treatment.
format Online
Article
Text
id pubmed-6972002
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69720022020-01-27 Routes of non-traditional entry into buprenorphine treatment programs Champagne-Langabeer, Tiffany Swank, Michael W. Langabeer, James R. Subst Abuse Treat Prev Policy Review BACKGROUND: Excessive prescribing, increased potency of opioids, and increased availability of illicit heroin and synthetic analogs such as fentanyl has resulted in an increase of overdose fatalities. Medications for opioid use disorder (MOUD) significantly reduces the risk of overdose when compared with no treatment. Although the use of buprenorphine as an agonist treatment for opioid use disorder (OUD) is growing significantly, barriers remain which can prevent or delay treatment. In this study we examine non-traditional routes which could facilitate entry into buprenorphine treatment programs. METHODS: Relevant, original research publications addressing entry into buprenorphine treatment published during the years 1989–2019 were identified through PubMed, PsychInfo, PsychArticles, and Medline databases. We operationalized key terms based on three non-traditional paths: persons that entered treatment via the criminal justice system, following emergencies, and through community outreach. RESULTS: Of 462 screened articles, twenty studies met the inclusion criteria for full review. Most studies were from the last several years, and most (65%) were from the Northeastern region of the United States. Twelve (60%) were studies suggesting that the criminal justice system could be a potentially viable entry route, both pre-release or post-incarceration. The emergency department was also found to be a cost-effective and viable route for screening and identifying individuals with OUD and linking them to buprenorphine treatment. Fewer studies have documented community outreach initiatives involving buprenorphine. Most studies were small sample size (mean = < 200) and 40% were randomized trials. CONCLUSIONS: Despite research suggesting that increasing the number of Drug Addiction Treatment Act (DATA) waived physicians who prescribe buprenorphine would help with the opioid treatment gap, little research has been conducted on routes to increase utilization of treatment. In this study, we found evidence that engaging individuals through criminal justice, emergency departments, and community outreach can serve as non-traditional treatment entry points for certain populations. Alternative routes could engage a greater number of people to initiate MOUD treatment. BioMed Central 2020-01-20 /pmc/articles/PMC6972002/ /pubmed/31959194 http://dx.doi.org/10.1186/s13011-020-0252-z Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Champagne-Langabeer, Tiffany
Swank, Michael W.
Langabeer, James R.
Routes of non-traditional entry into buprenorphine treatment programs
title Routes of non-traditional entry into buprenorphine treatment programs
title_full Routes of non-traditional entry into buprenorphine treatment programs
title_fullStr Routes of non-traditional entry into buprenorphine treatment programs
title_full_unstemmed Routes of non-traditional entry into buprenorphine treatment programs
title_short Routes of non-traditional entry into buprenorphine treatment programs
title_sort routes of non-traditional entry into buprenorphine treatment programs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972002/
https://www.ncbi.nlm.nih.gov/pubmed/31959194
http://dx.doi.org/10.1186/s13011-020-0252-z
work_keys_str_mv AT champagnelangabeertiffany routesofnontraditionalentryintobuprenorphinetreatmentprograms
AT swankmichaelw routesofnontraditionalentryintobuprenorphinetreatmentprograms
AT langabeerjamesr routesofnontraditionalentryintobuprenorphinetreatmentprograms